BeiGene, Ltd. (NASDAQ:BGNE) Receives $246.21 Average Price Target from Analysts

Shares of BeiGene, Ltd. (NASDAQ:BGNE) have been assigned a consensus recommendation of “Moderate Buy” from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $246.21.

A number of analysts have commented on BGNE shares. Citigroup upped their price target on shares of BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. JMP Securities started coverage on BeiGene in a research report on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd.

Insider Buying and Selling at BeiGene

In other news, CEO John Oyler sold 6,175 shares of the firm’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other BeiGene news, CEO John Oyler sold 6,175 shares of the business’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Chan Henry Lee sold 1,202 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $237.10, for a total transaction of $284,994.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,070 shares of company stock valued at $4,901,050. Corporate insiders own 7.43% of the company’s stock.

Hedge Funds Weigh In On BeiGene

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after purchasing an additional 75 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of BeiGene during the third quarter valued at $36,000. Headlands Technologies LLC acquired a new position in BeiGene during the first quarter valued at $50,000. SG Americas Securities LLC purchased a new stake in BeiGene in the 3rd quarter worth about $105,000. Finally, Acadian Asset Management LLC lifted its stake in BeiGene by 204.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock worth $197,000 after acquiring an additional 849 shares in the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Stock Performance

BGNE stock opened at $205.04 on Tuesday. The company has a 50-day simple moving average of $212.41 and a 200 day simple moving average of $180.94. The company has a market capitalization of $19.96 billion, a P/E ratio of -40.36 and a beta of 0.63. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. BeiGene has a fifty-two week low of $126.97 and a fifty-two week high of $248.16.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.